Authors
Xiangyang Lin, Xipeng Shen, Haitao Lou, Gang Ou, Kai Zhang
Published in
Immunopharmacology and immunotoxicology. Pages 1-12. Aug 24, 2026. Epub Aug 24, 2026.
Abstract
Isoflurane exhibits protective roles on ischemia-reperfusion injury (IRI), but whether isoflurane can alleviate the inflammation and oxidative stress of LIRI remains unknown.
To explore the effects of isoflurane treatment and HOXA11 antisense long noncoding RNA (HOXA11-AS) expression on LIRI.
AML12 cells were used to construct a hypoxia-reoxygenation (H/R) model. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was employed to test the HOXA11-AS level, microRNA-130b-3p, and phosphatase and tensin homolog (PTEN). Cell viability was detected using the cell counting kit-8 (CCK-8) kit. The content of intracellular inflammatory factors was detected using the enzyme‑linked immunosorbent assay (ELISA) kit. The positive rate of reactive oxygen species (ROS) was detected using 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA), and the contents of malondialdehyde (MDA) and superoxide dismutase (SOD) enzyme activities were detected using specialized kits. The dual luciferase reporter gene assay was used to verify the targeting relationship.
In the H/R model, the levels of HOXA11-AS and PTEN were increased, miR-130b-3p was decreased, cell viability was reduced, inflammatory factors level and oxidative stress were aggravated. The results showed an opposite trend with isoflurane pre-treatment. However, after HOXA11-AS overexpression, cell damage was further aggravated. HOXA11-AS is a molecular sponge for miR-130b-3p. It was revealed that the cell viability was improved, the inflammatory response and oxidative stress were weakened after transfection with miR-130b-3p mimic.
Isoflurane pretreatment reduced the level of HOXA11-AS, increased the level of miR-130b-3p, enhanced cell viability, and decreased cellular inflammatory factors level and oxidative stress in H/R model.
PMID:
42635097
Bibliographic data and abstract were imported from PubMed on 24 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0